Induced pluripotent stem cell‐based modeling of mutant LRRK2‐associated Parkinson's disease

Recent advances in cell reprogramming have enabled assessment of disease‐related cellular traits in patient‐derived somatic cells, thus providing a versatile platform for disease modeling and drug development. Given the limited access to vital human brain cells, this technology is especially relevant for neurodegenerative disorders such as Parkinson's disease (PD) as a tool to decipher underlying pathomechanisms. Importantly, recent progress in genome‐editing technologies has provided an ability to analyze isogenic induced pluripotent stem cell (iPSC) pairs that differ only in a single genetic change, thus allowing a thorough assessment of the molecular and cellular phenotypes that result from monogenetic risk factors. In this review, we summarize the current state of iPSC‐based modeling of PD with a focus on leucine‐rich repeat kinase 2 (LRRK2), one of the most prominent monogenetic risk factors for PD linked to both familial and idiopathic forms. The LRRK2 protein is a primarily cytosolic multi‐domain protein contributing to regulation of several pathways including autophagy, mitochondrial function, vesicle transport, nuclear architecture and cell morphology. We summarize iPSC‐based studies that contributed to improving our understanding of the function of LRRK2 and its variants in the context of PD etiopathology. These data, along with results obtained in our own studies, underscore the multifaceted role of LRRK2 in regulating cellular homeostasis on several levels, including proteostasis, mitochondrial dynamics and regulation of the cytoskeleton. Finally, we expound advantages and limitations of reprogramming technologies for disease modeling and drug development and provide an outlook on future challenges and expectations offered by this exciting technology.

[1]  W. Seol,et al.  LRRK2 impairs autophagy by mediating phosphorylation of leucyl‐tRNA synthetase , 2018, Cell biochemistry and function.

[2]  S. Pfeffer,et al.  A pathway for Parkinson’s Disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain , 2018, eLife.

[3]  Gwendolyn E. Kaeser,et al.  Somatic APP gene recombination in Alzheimer’s disease and normal neurons , 2018, Nature.

[4]  S. Russo,et al.  Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood , 2018, The Journal of Neuroscience.

[5]  A. Björklund,et al.  Target‐specific forebrain projections and appropriate synaptic inputs of hESC‐derived dopamine neurons grafted to the midbrain of parkinsonian rats , 2018, The Journal of comparative neurology.

[6]  A. Stepan,et al.  LRRK2 activation in idiopathic Parkinson’s disease , 2018, Science Translational Medicine.

[7]  Michael J. Devine,et al.  A single cell high content assay detects mitochondrial dysfunction in iPSC-derived neurons with mutations in SNCA , 2018, Scientific Reports.

[8]  D. Krainc,et al.  LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson’s disease , 2018, Proceedings of the National Academy of Sciences.

[9]  B. Klink,et al.  Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson's disease , 2018, PloS one.

[10]  P. Brundin,et al.  The concept of alpha-synuclein as a prion-like protein: ten years after , 2018, Cell and Tissue Research.

[11]  E. Bézard,et al.  Pharmacological Inhibition of Necroptosis Protects from Dopaminergic Neuronal Cell Death in Parkinson’s Disease Models , 2018, Cell reports.

[12]  R. Krüger,et al.  The genetic architecture of mitochondrial dysfunction in Parkinson’s disease , 2018, Cell and Tissue Research.

[13]  M. Cookson,et al.  LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network , 2018, Human molecular genetics.

[14]  Judy H. Cho,et al.  Functional variants in the LRRK2 gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease , 2018, Science Translational Medicine.

[15]  M. Cookson,et al.  The LRRK2 signalling system , 2018, Cell and Tissue Research.

[16]  Matheus B. Victor,et al.  Striatal neurons directly converted from Huntington’s disease patient fibroblasts recapitulate age-associated disease phenotypes , 2018, Nature Neuroscience.

[17]  M. Cookson,et al.  PAK6 Phosphorylates 14-3-3γ to Regulate Steady State Phosphorylation of LRRK2 , 2017, Front. Mol. Neurosci..

[18]  S. Pfeffer,et al.  Rab29 activation of the Parkinson's disease‐associated LRRK2 kinase , 2017, The EMBO journal.

[19]  T. Gasser,et al.  LRRK2 functions as a scaffolding kinase of ASK1-mediated neuronal cell death. , 2017, Biochimica et biophysica acta. Molecular cell research.

[20]  C. Chu,et al.  Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants , 2017, The Journal of Neuroscience.

[21]  Andrew J Schwab,et al.  Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons , 2017, Stem cell reports.

[22]  Malin Parmar,et al.  Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era. , 2017, Cell stem cell.

[23]  J. Jarazo,et al.  CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and α-Synuclein modulation in dopaminergic neurons. , 2017, Stem cell research.

[24]  R. Barker,et al.  Direct Neuronal Reprogramming for Disease Modeling Studies Using Patient-Derived Neurons: What Have We Learned? , 2017, Front. Neurosci..

[25]  Sohee Jeon,et al.  Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease , 2017, Science.

[26]  A. Heuer,et al.  Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation , 2017, Nature Protocols.

[27]  H. Houlden,et al.  Excess α-synuclein compromises phagocytosis in iPSC-derived macrophages , 2017, Scientific Reports.

[28]  Satoshi Morita,et al.  Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model , 2017, Nature.

[29]  L. Parkkinen,et al.  MAPT Genetic Variation and Neuronal Maturity Alter Isoform Expression Affecting Axonal Transport in iPSC-Derived Dopamine Neurons , 2017, Stem cell reports.

[30]  Nicholas W Wood,et al.  Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases , 2017, JAMA neurology.

[31]  R. Bodmer,et al.  SLP-2 interacts with Parkin in mitochondria and prevents mitochondrial dysfunction in Parkin-deficient human iPSC-derived neurons and Drosophila. , 2017, Human molecular genetics.

[32]  Giuseppe Testa,et al.  Taming Human Genetic Variability: Transcriptomic Meta-Analysis Guides the Experimental Design and Interpretation of iPSC-Based Disease Modeling , 2017, Stem cell reports.

[33]  C. Crosio,et al.  Role of LRRK2 in the regulation of dopamine receptor trafficking , 2017, PloS one.

[34]  R. Wade-Martins,et al.  The Role of Astrocyte Dysfunction in Parkinson’s Disease Pathogenesis , 2017, Trends in Neurosciences.

[35]  P. Bregestovski,et al.  Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson’s disease , 2017, Proceedings of the National Academy of Sciences.

[36]  Ronan M. T. Fleming,et al.  Derivation of Human Midbrain-Specific Organoids from Neuroepithelial Stem Cells , 2017, Stem cell reports.

[37]  W. James,et al.  LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease , 2017, Biochemical Society transactions.

[38]  A. Miyawaki,et al.  Efficient induction of dopaminergic neuron differentiation from induced pluripotent stem cells reveals impaired mitophagy in PARK2 neurons. , 2017, Biochemical and biophysical research communications.

[39]  D. James Surmeier,et al.  Selective neuronal vulnerability in Parkinson disease , 2017, Nature Reviews Neuroscience.

[40]  M. Hoehn,et al.  Whole-brain 3D mapping of human neural transplant innervation , 2017, Nature Communications.

[41]  C. Webber,et al.  Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson’s disease , 2017, Human molecular genetics.

[42]  Åsa K. Björklund,et al.  Single-Cell Analysis Reveals a Close Relationship between Differentiating Dopamine and Subthalamic Nucleus Neuronal Lineages. , 2017, Cell stem cell.

[43]  S. Dunnett,et al.  Predictive Markers Guide Differentiation to Improve Graft Outcome in Clinical Translation of hESC-Based Therapy for Parkinson’s Disease , 2017, Cell stem cell.

[44]  B. Shaby,et al.  Nrf2 mitigates LRRK2- and α-synuclein–induced neurodegeneration by modulating proteostasis , 2016, Proceedings of the National Academy of Sciences.

[45]  F. Chew,et al.  Genome-wide association study of Parkinson’s disease in East Asians , 2016, Human molecular genetics.

[46]  E. Topol,et al.  Influence of donor age on induced pluripotent stem cells , 2016, Nature Biotechnology.

[47]  M. Cookson,et al.  LRRK2 at the interface of autophagosomes, endosomes and lysosomes , 2016, Molecular Neurodegeneration.

[48]  Xinnan Wang,et al.  Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson's Disease. , 2016, Cell stem cell.

[49]  V. Lang,et al.  Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons , 2016, Journal of Neuroinflammation.

[50]  M. Cookson,et al.  mTOR independent regulation of macroautophagy by Leucine Rich Repeat Kinase 2 via Beclin-1 , 2016, Scientific Reports.

[51]  W. Le,et al.  Protective Microglia and Their Regulation in Parkinson’s Disease , 2016, Front. Mol. Neurosci..

[52]  Matheus B. Victor,et al.  Maintenance of age in human neurons generated by microRNA-based neuronal conversion of fibroblasts , 2016, eLife.

[53]  Pierre Maquet,et al.  Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects , 2016, Scientific Reports.

[54]  A. Mrejeru,et al.  Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation , 2016, Stem cell reports.

[55]  H. Cai,et al.  LRRK2 modulates microglial activity through regulation of chemokine (C-X3-C) receptor 1 -mediated signalling pathways. , 2016, Human molecular genetics.

[56]  Daniel R Weinberger,et al.  Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons. , 2016, Cell stem cell.

[57]  D. Krainc,et al.  Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons , 2016, The Journal of Neuroscience.

[58]  Zayd M. Khaliq,et al.  A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism , 2016, The Journal of Neuroscience.

[59]  B. Matikainen-Ankney,et al.  Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2–G2019S Mutation , 2016, The Journal of Neuroscience.

[60]  A. Schapira,et al.  Molecular changes in the postmortem parkinsonian brain , 2016, Journal of neurochemistry.

[61]  E. Gerhardt,et al.  LRRK2 Promotes Tau Accumulation, Aggregation and Release , 2015, Molecular Neurobiology.

[62]  Mark R Dranias,et al.  Molecular Features Underlying Neurodegeneration Identified through In Vitro Modeling of Genetically Diverse Parkinson's Disease Patients. , 2016, Cell reports.

[63]  Su-Chun Zhang,et al.  Chemical Control of Grafted Human PSC-Derived Neurons in a Mouse Model of Parkinson's Disease. , 2016, Cell stem cell.

[64]  E. Ziviani,et al.  Mitochondrial dynamics and mitophagy in Parkinson's disease: A fly point of view , 2016, Neurobiology of Disease.

[65]  G. Piccoli,et al.  LRRK2 Regulates Voltage-Gated Calcium Channel Function , 2016, Front. Mol. Neurosci..

[66]  A. Kortholt,et al.  Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson's Disease , 2016, Parkinson's disease.

[67]  Thomas C. Südhof,et al.  Autism-associated SHANK3 haploinsufficiency causes Ih channelopathy in human neurons , 2016, Science.

[68]  Yih-Ru Wu,et al.  Impairment of proteasome and anti-oxidative pathways in the induced pluripotent stem cell model for sporadic Parkinson's disease. , 2016, Parkinsonism & related disorders.

[69]  H. Christian,et al.  ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons , 2016, Stem cell reports.

[70]  S. Yamanaka,et al.  A decade of transcription factor-mediated reprogramming to pluripotency , 2016, Nature Reviews Molecular Cell Biology.

[71]  D. Krainc,et al.  α-Synuclein–induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models , 2016, Proceedings of the National Academy of Sciences.

[72]  L. Abel,et al.  A Missense LRRK2 Variant Is a Risk Factor for Excessive Inflammatory Responses in Leprosy , 2016, PLoS neglected tropical diseases.

[73]  Matthias Mann,et al.  Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases , 2016, eLife.

[74]  N. Benvenisty,et al.  Pluripotent stem cells in disease modelling and drug discovery , 2016, Nature Reviews Molecular Cell Biology.

[75]  J. Kettunen,et al.  Genetic Variability Overrides the Impact of Parental Cell Type and Determines iPSC Differentiation Potential , 2016, Stem cell reports.

[76]  S. Cragg,et al.  LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function , 2016, Human molecular genetics.

[77]  L. Bubacco,et al.  Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells , 2015, Journal of Neuroinflammation.

[78]  Andrew J Schwab,et al.  Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson’s Disease-Related LRRK2 G2019S Mutation , 2015, Stem cell reports.

[79]  Jürgen Winkler,et al.  Directly Reprogrammed Human Neurons Retain Aging-Associated Transcriptomic Signatures and Reveal Age-Related Nucleocytoplasmic Defects. , 2015, Cell stem cell.

[80]  M. Cookson,et al.  Leucine‐rich repeat kinase 2 interacts with p21‐activated kinase 6 to control neurite complexity in mammalian brain , 2015, Journal of neurochemistry.

[81]  Peter J. Park,et al.  Somatic mutation in single human neurons tracks developmental and transcriptional history , 2015, Science.

[82]  Martin Lévesque,et al.  Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons , 2015, Current Biology.

[83]  Sung Hoon Baik,et al.  LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase , 2015, Nature Communications.

[84]  Marius Wernig,et al.  Human Neuropsychiatric Disease Modeling using Conditional Deletion Reveals Synaptic Transmission Defects Caused by Heterozygous Mutations in NRXN1. , 2015, Cell stem cell.

[85]  H. Okano,et al.  I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway. , 2015, Human molecular genetics.

[86]  R. Blitzer,et al.  The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus , 2015, The Journal of Neuroscience.

[87]  Stephanie L. Alberico,et al.  The Vulnerable Ventral Tegmental Area in Parkinson's Disease. , 2015, Basal ganglia.

[88]  T. Ideker,et al.  Evolutionary trends and functional anatomy of the human expanded autophagy network , 2015, Autophagy.

[89]  E. Arenas,et al.  How to make a midbrain dopaminergic neuron , 2015, Development.

[90]  Angeleen Fleming,et al.  Compromised autophagy and neurodegenerative diseases , 2015, Nature Reviews Neuroscience.

[91]  F. Clascá,et al.  Long-range projection neurons of the mouse ventral tegmental area: a single-cell axon tracing analysis , 2015, Front. Neuroanat..

[92]  C. Manzoni,et al.  Cellular processes associated with LRRK2 function and dysfunction , 2015, The FEBS journal.

[93]  M. Rao,et al.  Mitochondrial Alterations by PARKIN in Dopaminergic Neurons Using PARK2 Patient-Specific and PARK2 Knockout Isogenic iPSC Lines , 2015, Stem cell reports.

[94]  Richard Wade-Martins,et al.  Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. , 2015, Trends in biochemical sciences.

[95]  Maria Sundberg,et al.  Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. , 2015, Cell stem cell.

[96]  A. Minervina,et al.  The Evidence for Increased L1 Activity in the Site of Human Adult Brain Neurogenesis , 2015, PloS one.

[97]  Hongqi Zhang,et al.  Defective Autophagy in Parkinson’s Disease: Lessons from Genetics , 2015, Molecular Neurobiology.

[98]  Karl Deisseroth,et al.  Optogenetics enables functional analysis of human embryonic stem cell–derived grafts in a Parkinson's disease model , 2015, Nature Biotechnology.

[99]  S. Ge,et al.  Parkin Mutations Reduce the Complexity of Neuronal Processes in iPSC‐Derived Human Neurons , 2015, Stem cells.

[100]  P. Greengard,et al.  Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update , 2014, Front. Neuroanat..

[101]  D. Goldstein,et al.  Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. , 2014, Pharmacology & therapeutics.

[102]  Eric E Schadt,et al.  iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease. , 2014, Cell reports.

[103]  R. Jaenisch,et al.  Higher Vulnerability and Stress Sensitivity of Neuronal Precursor Cells Carrying an Alpha-Synuclein Gene Triplication , 2014, PloS one.

[104]  L. Tan,et al.  The role of the LRRK2 gene in Parkinsonism , 2014, Molecular Neurodegeneration.

[105]  A. Björklund,et al.  Human ESC-Derived Dopamine Neurons Show Similar Preclinical Efficacy and Potency to Fetal Neurons when Grafted in a Rat Model of Parkinson’s Disease , 2014, Cell stem cell.

[106]  X. Chen,et al.  Leucine‐rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER–Golgi export , 2014, The EMBO journal.

[107]  M. Parmar,et al.  Highly efficient generation of induced neurons from human fibroblasts that survive transplantation into the adult rat brain , 2014, Scientific Reports.

[108]  P. Lucassen,et al.  Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson’s disease patients , 2014, Acta Neuropathologica Communications.

[109]  L. Civiero,et al.  Genetic, Structural, and Molecular Insights into the Function of Ras of Complex Proteins Domains , 2014, Chemistry & biology.

[110]  H. Cai,et al.  Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation. , 2014, The Journal of clinical investigation.

[111]  S. Gygi,et al.  iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis , 2014, Nature Communications.

[112]  Lisle W. Blackbourn,et al.  Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. , 2014, Cell stem cell.

[113]  Daniel J. Gaffney,et al.  Genetic Background Drives Transcriptional Variation in Human Induced Pluripotent Stem Cells , 2014, PLoS genetics.

[114]  P. Kahle,et al.  Interferon‐γ induces leucine‐rich repeat kinase LRRK2 via extracellular signal‐regulated kinase ERK5 in macrophages , 2014, Journal of neurochemistry.

[115]  E. Fedele,et al.  LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex , 2014, Front. Mol. Neurosci..

[116]  L. Zhang,et al.  Mitochondrial dysfunction driven by the LRRK2-mediated pathway is associated with loss of Purkinje cells and motor coordination deficits in diabetic rat model , 2014, Cell Death and Disease.

[117]  L. Bubacco,et al.  LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease? , 2014, Journal of Neuroinflammation.

[118]  K. Sekiguchi,et al.  Isolation of Human Induced Pluripotent Stem Cell-Derived Dopaminergic Progenitors by Cell Sorting for Successful Transplantation , 2014, Stem cell reports.

[119]  Nicole A. Crowley,et al.  LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity , 2014, Nature Neuroscience.

[120]  Suneil K. Kalia,et al.  Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease , 2014, Proceedings of the National Academy of Sciences.

[121]  J. Langston,et al.  LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: Reversal by gene correction , 2014, Neurobiology of Disease.

[122]  V. Tabar,et al.  Pluripotent stem cells in regenerative medicine: challenges and recent progress , 2014, Nature Reviews Genetics.

[123]  M. Cookson,et al.  Mutant LRRK2 Toxicity in Neurons Depends on LRRK2 Levels and Synuclein But Not Kinase Activity or Inclusion Bodies , 2014, The Journal of Neuroscience.

[124]  Fumitaka Kawakami,et al.  Leucine‐rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase‐3β , 2014, The FEBS journal.

[125]  D. Krainc,et al.  Human iPSC-based modeling of late-onset disease via progerin-induced aging. , 2013, Cell stem cell.

[126]  John R. Yates,et al.  Isogenic Human iPSC Parkinson’s Model Shows Nitrosative Stress-Induced Dysfunction in MEF2-PGC1α Transcription , 2013, Cell.

[127]  A. Siddiqui,et al.  Hepatitis B Virus Disrupts Mitochondrial Dynamics: Induces Fission and Mitophagy to Attenuate Apoptosis , 2013, PLoS pathogens.

[128]  T. Dawson,et al.  Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily , 2013, Human molecular genetics.

[129]  X. Qi,et al.  Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. , 2013, Human molecular genetics.

[130]  T. Dawson,et al.  LRRK2 Affects Vesicle Trafficking, Neurotransmitter Extracellular Level and Membrane Receptor Localization , 2013, PloS one.

[131]  S. Horvath.  DNA methylation age of human tissues and cell types , 2013, Genome Biology.

[132]  D. Maraganore,et al.  Population‐specific frequencies for LRRK2 susceptibility variants in the genetic epidemiology of Parkinson's disease (GEO‐PD) consortium , 2013, Movement disorders : official journal of the Movement Disorder Society.

[133]  K. Double,et al.  Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra , 2013, Movement disorders : official journal of the Movement Disorder Society.

[134]  Madeline A. Lancaster,et al.  Cerebral organoids model human brain development and microcephaly , 2013, Nature.

[135]  K. Thangaraj,et al.  LRRK2 and RIPK2 Variants in the NOD 2-Mediated Signaling Pathway Are Associated with Susceptibility to Mycobacterium leprae in Indian Populations , 2013, PloS one.

[136]  T. Südhof,et al.  Rapid Single-Step Induction of Functional Neurons from Human Pluripotent Stem Cells , 2013, Neuron.

[137]  A. Björklund,et al.  Generation of induced neurons via direct conversion in vivo , 2013, Proceedings of the National Academy of Sciences.

[138]  Thomas Gasser,et al.  Derivation and Expansion Using Only Small Molecules of Human Neural Progenitors for Neurodegenerative Disease Modeling , 2013, PloS one.

[139]  J. Paul Bolam,et al.  The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease , 2013, Front. Comput. Neurosci..

[140]  A. Chiang,et al.  Loss of vesicular dopamine release precedes tauopathy in degenerative dopaminergic neurons in a Drosophila model expressing human tau , 2013, Acta Neuropathologica.

[141]  Torsten Kluba,et al.  Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. , 2013, Cell stem cell.

[142]  K. Marder,et al.  RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson’s Disease Risk , 2013, Neuron.

[143]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[144]  A. Consiglio,et al.  Interplay of LRRK2 with chaperone-mediated autophagy , 2013, Nature Neuroscience.

[145]  K. Marder,et al.  RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson’s Disease Risk , 2013, Neuron.

[146]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[147]  Yoshiki Sasai,et al.  Cytosystems dynamics in self-organization of tissue architecture , 2013, Nature.

[148]  B. Ritz,et al.  Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease , 2012, Proceedings of the National Academy of Sciences.

[149]  K. Scearce-Levie,et al.  Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations , 2012, Science Translational Medicine.

[150]  P. Gomez-Suaga,et al.  A Link between Autophagy and the Pathophysiology of LRRK2 in Parkinson's Disease , 2012, Parkinson's disease.

[151]  David C. Wilson,et al.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.

[152]  H. Okano,et al.  Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue , 2012, Molecular Brain.

[153]  J. Yates,et al.  Progressive degeneration of human neural stem cells caused by pathogenic LRRK2 , 2012, Nature.

[154]  J. Bolam,et al.  Living on the edge with too many mouths to feed: Why dopamine neurons die , 2012, Movement disorders : official journal of the Movement Disorder Society.

[155]  K. Zaghloul,et al.  K-ATP channels in dopamine substantia nigra neurons control bursting and novelty-induced exploration , 2012, Nature Neuroscience.

[156]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[157]  M. Emborg,et al.  Specification of Midbrain Dopamine Neurons from Primate Pluripotent Stem Cells , 2012, Stem cells.

[158]  Christine Klein,et al.  Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease , 2012, Science Translational Medicine.

[159]  O. Lindvall,et al.  Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. , 2012, Cell reports.

[160]  Patrick G. A. Pedrioli,et al.  The IkappaB Kinase Family Phosphorylates the Parkinson’s Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling , 2012, PloS one.

[161]  M. Memo,et al.  Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease , 2012, EMBO molecular medicine.

[162]  Robert Clarke,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy , 2012 .

[163]  Xiongwei Zhu,et al.  LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. , 2012, Human molecular genetics.

[164]  Zhen Yan,et al.  Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells , 2012, Nature Communications.

[165]  D. Surmeier,et al.  Floor plate-derived dopamine neurons from hESCs efficiently engraft in animal models of PD , 2011, Nature.

[166]  Lief E. Fenno,et al.  SNCA Triplication Parkinson's Patient's iPSC-derived DA Neurons Accumulate α-Synuclein and Are Susceptible to Oxidative Stress , 2011, PloS one.

[167]  Wei Lu,et al.  The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease , 2011, Nature Immunology.

[168]  G. Churchill,et al.  Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP , 2011, Human molecular genetics.

[169]  J. Ioannidis,et al.  Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study , 2011, The Lancet Neurology.

[170]  Maria Teresa Dell'Anno,et al.  Direct generation of functional dopaminergic neurons from mouse and human fibroblasts , 2011, Nature.

[171]  A. Brice,et al.  Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease. , 2011, Parkinsonism & related disorders.

[172]  Ying Sun,et al.  Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies , 2011, Cell.

[173]  A. Joyner,et al.  Temporal-spatial changes in Sonic Hedgehog expression and signaling reveal different potentials of ventral mesencephalic progenitors to populate distinct ventral midbrain nuclei , 2011, Neural Development.

[174]  Ulrich Pfisterer,et al.  Direct conversion of human fibroblasts to dopaminergic neurons , 2011, Proceedings of the National Academy of Sciences.

[175]  Thomas Vierbuchen,et al.  Induction of human neuronal cells by defined transcription factors , 2011, Nature.

[176]  D. Krainc,et al.  Mitochondrial Parkin Recruitment Is Impaired in Neurons Derived from Mutant PINK1 Induced Pluripotent Stem Cells , 2011, The Journal of Neuroscience.

[177]  D. Surmeier,et al.  The origins of oxidant stress in Parkinson's disease and therapeutic strategies. , 2011, Antioxidants & redox signaling.

[178]  Blake Byers,et al.  LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. , 2011, Cell stem cell.

[179]  Mark R. Cookson,et al.  The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease , 2010, Nature Reviews Neuroscience.

[180]  Tariq Ahmad,et al.  Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci , 2010, Nature Genetics.

[181]  M. Ungless,et al.  Hyperexcitable substantia nigra dopamine neurons in PINK1- and HtrA2/Omi-deficient mice. , 2010, Journal of neurophysiology.

[182]  H. Cai,et al.  LRRK2 function on actin and microtubule dynamics in Parkinson’s disease , 2010, Communicative & integrative biology.

[183]  Z. Berger,et al.  Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. , 2010, Biochemistry.

[184]  K. Anderson,et al.  The primary cilium: a signalling centre during vertebrate development , 2010, Nature Reviews Genetics.

[185]  Thomas Vierbuchen,et al.  Direct conversion of fibroblasts to functional neurons by defined factors , 2010, Nature.

[186]  J. Son,et al.  PINK1 gene knockdown leads to increased binding of parkin with actin filament , 2010, Neuroscience Letters.

[187]  R. Awatramani,et al.  Spatiotemporally separable Shh domains in the midbrain define distinct dopaminergic progenitor pools , 2009, Proceedings of the National Academy of Sciences.

[188]  J. Callaway,et al.  Endogenous calcium buffering capacity of substantia nigral dopamine neurons. , 2009, Journal of neurophysiology.

[189]  C. Warren Olanow,et al.  Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions , 2009, Neurobiology of Disease.

[190]  Gene W. Yeo,et al.  L1 retrotransposition in human neural progenitor cells , 2009, Nature.

[191]  P. Lewis.  The function of ROCO proteins in health and disease , 2009, Biology of the cell.

[192]  F. Fujiyama,et al.  Single Nigrostriatal Dopaminergic Neurons Form Widely Spread and Highly Dense Axonal Arborizations in the Neostriatum , 2009, The Journal of Neuroscience.

[193]  Kostas Vekrellis,et al.  Wild Type α-Synuclein Is Degraded by Chaperone-mediated Autophagy and Macroautophagy in Neuronal Cells* , 2008, Journal of Biological Chemistry.

[194]  S. Lammel,et al.  Unique Properties of Mesoprefrontal Neurons within a Dual Mesocorticolimbic Dopamine System , 2008, Neuron.

[195]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[196]  J. Takahashi,et al.  Differences in neurogenic potential in floor plate cells along an anteroposterior location: midbrain dopaminergic neurons originate from mesencephalic floor plate cells , 2007, Development.

[197]  S. Asakawa,et al.  Parkin interacts with LIM Kinase 1 and reduces its cofilin-phosphorylation activity via ubiquitination. , 2007, Experimental cell research.

[198]  R. Nichols,et al.  LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. , 2007, The Biochemical journal.

[199]  M. Cookson,et al.  The R1441C mutation of LRRK2 disrupts GTP hydrolysis. , 2007, Biochemical and biophysical research communications.

[200]  Dwight C. German,et al.  Mitochondria mass is low in mouse substantia nigra dopamine neurons: Implications for Parkinson's disease , 2007, Experimental Neurology.

[201]  K. Lim,et al.  Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. , 2007, Human molecular genetics.

[202]  M. Farrer,et al.  Parkinsonism, Lrrk2 G2019S, and tau neuropathology , 2006, Neurology.

[203]  Tetsuaki Arai,et al.  LRRK2 Expression in Normal and Pathologic Human Brain and in Human Cell Lines , 2006, Journal of neuropathology and experimental neurology.

[204]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[205]  L. Petrucelli,et al.  Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model , 2006, Neuroscience Letters.

[206]  Matthew J. Farrer,et al.  LRRK2 in Parkinson's disease: protein domains and functional insights , 2006, Trends in Neurosciences.

[207]  J. Miklossy,et al.  Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys , 2006, Experimental Neurology.

[208]  Alexander Hammers,et al.  In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease , 2006, Neurobiology of Disease.

[209]  T. Meitinger,et al.  The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. , 2006, Human molecular genetics.

[210]  T. Nägele,et al.  Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. , 2005, Brain : a journal of neurology.

[211]  Jochen Roeper,et al.  K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons , 2005, Nature Neuroscience.

[212]  D. Dickson,et al.  Tau gene transfer, but not alpha-synuclein, induces both progressive dopamine neuron degeneration and rotational behavior in the rat , 2005, Neurobiology of Disease.

[213]  A. Dagher,et al.  Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. , 2005, Brain : a journal of neurology.

[214]  Fred H. Gage,et al.  Somatic mosaicism in neuronal precursor cells mediated by L1 retrotransposition , 2005, Nature.

[215]  D. Soll,et al.  RasGEF-containing proteins GbpC and GbpD have differential effects on cell polarity and chemotaxis in Dictyostelium , 2005, Journal of Cell Science.

[216]  Timothy Lynch,et al.  Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. , 2005, American journal of human genetics.

[217]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[218]  V. Tabar,et al.  Derivation of midbrain dopamine neurons from human embryonic stem cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[219]  D. Sulzer,et al.  Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics , 2003, Trends in Neurosciences.

[220]  Makoto Sawada,et al.  Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains , 2003, Acta Neuropathologica.

[221]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[222]  R. Marconi,et al.  Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7 , 2002, Neurological Sciences.

[223]  P. Bywood,et al.  Differential Vulnerabilities of Substantia Nigra Catecholamine Neurons to Excitatory Amino Acid-Induced Degeneration in Rat Midbrain Slices , 2000, Experimental Neurology.

[224]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[225]  P. Damier,et al.  Glial cells and inflammation in parkinson's disease: A role in neurodegeneration? , 1998, Annals of neurology.

[226]  D. Bumcrot,et al.  Sonic Hedgehog Promotes the Survival of Specific CNS Neuron Populations and Protects These Cells from Toxic Insult In Vitro , 1997, The Journal of Neuroscience.

[227]  M. Vawter,et al.  TGFβ1 and TGFβ2 Concentrations Are Elevated in Parkinson's Disease in Ventricular Cerebrospinal Fluid , 1996, Experimental Neurology.

[228]  Alessandro Stefani,et al.  Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones , 1994, British journal of pharmacology.

[229]  I. Engberg,et al.  Nifedipine‐ and omega‐conotoxin‐sensitive Ca2+ conductances in guinea‐pig substantia nigra pars compacta neurones. , 1993, The Journal of physiology.

[230]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[231]  R. Duvoisin,et al.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.

[232]  M. Demirci.  Comprehensive Clinical Nephrology 3rd Edition , 2011 .

[233]  J. T. Greenamyre,et al.  Neurotoxic in vivo models of Parkinson's disease recent advances. , 2010, Progress in brain research.

[234]  A. Cuervo,et al.  Methods to monitor chaperone-mediated autophagy. , 2009, Methods in enzymology.

[235]  Oliver Brüstle,et al.  Automated maintenance of embryonic stem cell cultures , 2007, Biotechnology and bioengineering.

[236]  Y. Agid,et al.  Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. , 1997, Histology and histopathology.

[237]  M. Vawter,et al.  TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. , 1996, Experimental neurology.